Flerie AB (STU:1NP1) EBIT: €-66.52 Mil (TTM As of Mar. 2026)

What is Flerie AB EBIT?

Flerie AB STU:1NP1 -1.15% 35 EBIT is €-66.52 Mil as of Mar. 2026. GuruFocus rates STU:1NP1 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Flerie AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-5.22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-66.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Flerie AB's annualized ROC % for the quarter that ended in Mar. 2026 was -1.59%. Flerie AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14,150.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Flerie AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -63.54%.

Flerie AB (STU:1NP1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Flerie AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-4.384 * ( 1 - 0.16% )	/	( (262.398	+	287.643)	/ 2 )
=	-4.3769856	/	275.0205
=	-1.59 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	312.176	-	0.138	-	( 49.64	-	max(0, 1.277	-	66.815	+	49.64	))
=	262.398

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	342.019	-	0.056	-	( 54.32	-	max(0, 0.724	-	72.712	+	54.32	))
=	287.643

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Flerie AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-20.872	/	( ( (0.156 + max(-0.30300000000001, 0))	+	(0.139 + max(-0.074000000000005, 0)) )	/	2 )
=	-20.872	/	( ( 0.156	+	0.139 )	/	2 )
=	-20.872	/	0.1475
=	-14,150.51 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.055	+	0	+	0.87299999999999)	-	(0.138	+	0	+	1.093)
=	-0.30300000000001

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.102	+	0	+	0.502)	-	(0.056	+	0	+	0.622)
=	-0.074000000000005

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Flerie AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-66.52	/	104.688
	=	-63.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Flerie AB EBIT Related Terms

Flerie AB EBIT Historical Data

* Premium members only.

The historical data trend for Flerie AB's EBIT can be seen below:

Flerie AB EBIT Chart

Flerie AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-10.02

-9.12

-48.66

-19.69

-69.57

Flerie AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-15.45	-0.32	-12.23	-48.76	-5.22

STU:1NP1 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Flerie AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flerie AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Flerie AB's EV-to-EBIT falls into.

Save Embed

35GF Score

Flerie AB STU:1NP1

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Flerie AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-66.52 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-66.52 Mil mean?

Flerie AB (STU:1NP1) has a EBIT of €-66.52 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Flerie AB.

Is Flerie AB's EBIT too high?

Flerie AB's current EBIT is €-66.52 Mil. Overall, Flerie AB has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Flerie AB's EBIT compare to VRTX and REGN?

Flerie AB's EBIT of €-66.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Flerie AB. Flerie AB's current EBIT is €-66.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Flerie AB stock overvalued right now?

Flerie AB (STU:1NP1) has a current EBIT of €-66.52 Mil. The current EBIT is €-66.52 Mil. Flerie AB's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Flerie AB (STU:1NP1), the current EBIT is €-66.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Flerie AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:SANION OSTO:BINV XSAT:CURAS XSAT:HAMLET B OSTO:GENO OSTO:MVIR OSTO:EGTX OSTO:SYNACT OSTO:IBT B OSTO:XSPRAY VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges FLERIE:Sweden

Address Skeppsbron 16, Stockholm, SWE, 111 30

Website https://www.flerie.com

Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.

35GF Score

Get the complete analysis for STU:1NP1

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.72

Price

View STU:1NP1 Analysis

See EBIT data for all stocks →